Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG on July 14 and set a price target of CHF106.00. The company’s shares closed yesterday at CHF96.06. Elev ...

Reproducible translation of transcriptomics data has been hampered by the ubiquitous presence of batch effects. Statistical methods for managing batch effects were initially developed in the setting ...

In a report released yesterday, Kerry Holford from Berenberg Bank maintained a Hold rating on Novartis, with a price target of $108.00. The company’s shares closed yesterday at $122.94. According to ...

IGI Therapeutics SA, has signed with Abbvie Inc. a global licensing partnership for trispecific antibody ISB-2001 worth $1.925 billion plus royalties. ISB-2001, which targets BCMA, CD38 and CD3, is in ...

Novartis has inked a deal with Sironax that gives the pharma the exclusive option to acquire the biotech’s blood-brain ...

Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for age-related diseases, today announced a strategic agreement with Novartis under ...

Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

Baseus Unveils Revolutionary EnerCore Charging Solutions, Eliminating Cable Clutter Without CompromiseDisclaimer The content, including but not limited to any articles, news, quotes, information, data ...

CAMBRIDGE, MA, USA I June 30, 2025 I XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine ...

NEW YORK, NY, USA I June 23, 2025 I Formation Bio, an AI-native pharma company focused on accelerating drug development, today announced that its subsidiary Libertas Bio has licensed gusacitinib, an ...